RNA-based Gene therapy for the treatment and prevention of HIV: From Bench to Bedside

Yale Journal of Biology and Medicine

Volumn 84, Issue 3, 2011, Pages 301-309

  Zeller, Skye J ^a   Kumar, Priti ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aptamer HIV; Clinical Trial HIV; Gene therapy HIV; Ribozyme HIV; RNAi HIV

Indexed keywords

ANTIRETROVIRUS AGENT; ANTISENSE OLIGONUCLEOTIDE; APTAMER; HAIRPIN RIBOZYME; HAMMERHEAD RIBOZYME; LENTIVIRUS VECTOR; NEVIRAPINE; PLACEBO; RETROVIRUS VECTOR; RIBOZYME; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD34 ANTIGEN;

ANTISENSE THERAPY; ANTIVIRAL ACTIVITY; CELL BASED GENE THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EX VIVO GENE TRANSFER; GENE THERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NONHUMAN; REVIEW; RNA INTERFERENCE; UNSPECIFIED SIDE EFFECT; VIRUS INHIBITION; CD4+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); GENE VECTOR; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; LONG TERMINAL REPEAT; METABOLISM; METHODOLOGY; PATHOGENICITY; PHYSIOLOGY; VIROLOGY; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIGENS, CD34; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; APTAMERS, NUCLEOTIDE; CD4-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; GENE THERAPY; GENETIC VECTORS; HIV; HIV INFECTIONS; HIV LONG TERMINAL REPEAT; HUMANS; RNA INTERFERENCE; RNA, CATALYTIC; RNA, SMALL INTERFERING; VIRUS REPLICATION;

EID: 84856204035     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. World Health Organization: Global Epidemic Data and Statistics 2010 [Internet]. Available from: http://www.who.int/hiv/data/global_data/en/index.html.
2. Scherer L, Rossi J, Weinberg M. Progress and prospects: RNA-based therapies for treatment of HIV infection. Gene Ther. 2007;14(14):1057-64.
3. Birikh K, Heaton P, Eckstein F. The structure, function and application of the hammerhead ribozyme. Eur J Biochem. 1997;245(1):1-16.
4. Citti L, Rainaldi G. Synthetic hammerhead ribozymes as therapeutic tools to control disease genes. Curr Gene Ther. 2005;5(1):11-24.
5. Duarte E, Leavitt M, Yamada O, Yu M. Hairpin ribozyme gene therapy for AIDS. Methods Mol Biol. 1997;74:459-68.
6. Wong-Staal F, Poeschla E, Looney D. A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Hum Gene Ther. 1998;9(16):2407-25.
7. Ojwang J, Hampel A, Looney D, Wong-Staal F, Rappaport J. Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. Proc Natl Acad Sci USA. 1992;89(22):10802-6.
8. Yu M, Poeschla E, Yamada O, Degrandis P, Leavitt M, Heusch M, et al. In vitro and in vivo characterization of a second functional hairpin ribozyme against HIV-1. Virology. 1995;206(1):381-6.
9. Yamada O, Kraus G, Luznik L, Yu M, Wong-Staal F. A chimeric human immunodeficiency virus type 1 (HIV-1) minimal Rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1. J Virol. 1996;70(3):1596-601.
10. Gervaix A, Li X, Kraus G, Wong-Staal F. Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades. J Virol. 1997;71(4):3048-53.
11. Leavitt M, Yu M, Yamada O, Kraus G, Looney D, Poeschla E, et al. Transfer of an anti-HIV-1 ribozyme gene into primary human lymphocytes. Hum Gene Ther. 1994;5(9):1115-20.
12. Krüger M, Beger C, Wong-Staal F. Use of ribozymes to inhibit gene expression. Methods Enzymol. 1999;306:207-25.
13. Zhou C, Bahner I, Larson G, Zaia J, Rossi J, Kohn E. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene. 1994;149(1):33-9.
14. Bauer G, Valdez P, Kearns K, Bahner I, Wen S, Zaia J, et al. Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. Blood. 1997;89(7):2259-67.
15. Michienzi A, Castanotto D, Lee N, Li S, Zaia J, Rossi J. RNA-mediated inhibition of HIV in a gene therapy setting. Ann NY Acad Sci. 2003;1002:63-71.
16. Michienzi A, Castanotto D, Lee N, Li S, Zaia JA, Rossi JJ. Novel ribozyme, RNA decoy, and siRNA approaches to inhibition of HIV in a gene therapy setting. Clinical and Applied Immunology Reviews. 2003;3(4-5):223-33.
17. Burnett J, Rossi J. Stem cells, ribozymes and HIV. Gene Ther. 2009;16(10):1178-9.
18. Sun L, Pyati J, Smythe J, Wang L, Macpherson J, Gerlach W, et al. Resistance to human immunodeficiency virus type 1 infection conferred by transduction of human peripheral blood lymphocytes with ribozyme, antisense, or polymeric trans-activation response element constructs. Proc Natl Acad Sci USA. 1995;92(16):7272-6.
19. Sun L, Wang L, Gerlach W, Symonds G. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA. Nucleic Acids Res. 1995;23(15):2909-13.
20. Wang L, Witherington C, King A, Gerlach W, Carr A, Penny R, et al. Preclinical characterization of an anti-tat ribozyme for therapeutic application. Hum Gene Ther. 1998;9(9):1283-91.
21. Amado R, Mitsuyasu R, Symonds G, Rosenblatt J, Zack J, Sun L, et al. A phase I trial of autologous CD34+ hematopoietic progenitor cells transduced with an anti-HIV ribozyme. Hum Gene Ther. 1999;10(13):2255-70.
22. Cooper D, Penny R, Symonds G, Carr A, Gerlach W, Sun L, et al. A marker study of therapeutically transduced CD4+ peripheral blood lymphocytes in HIV discordant identical twins. Hum Gene Ther. 1999;10(8):1401-21.
23. Macpherson J, Boyd M, Arndt A, Todd A, Fanning G, Ely J, et al. Long-term survival and concomitant gene expression of ribozymetransduced CD4+ T-lymphocytes in HIV-infected patients. J Gene Med. 2005;7(5):552-64.
24. Amado R, Mitsuyasu R, Rosenblatt J, Ngok F, Bakker A, Cole S, et al. Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum Gene Ther. 2004;15(3):251-62.
25. Mitsuyasu R, Merigan T, Carr A, Zack J, Winters M, Workman C, et al. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med. 2009;15(3):285-92.
26. DiGiusto D, Krishnan A, Li L, Li H, Li S, Rao A, et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med. 2010;2(36):36-43.
27. Michienzi A, Li S, Zaia J, Rossi J. A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc Natl Acad Sci USA. 2002;99(22):14047-52.
28. Cagnon L, Rossi J. Downregulation of the CCR5 beta-chemokine receptor and inhibition of HIV-1 infection by stable VA1-ribozyme chimeric transcripts. Antisense Nucleic Acid Drug Dev. 2000;10(4):251-61.
29. Li M, Bauer G, Michienzi A, Yee J, Lee N, Kim J, et al. Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther. 2003;8(2):196-206.
30. Li M, Kim J, Li S, Zaia J, Yee J, Anderson J, et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther. 2005;12(5):900-9.
31. Anderson J, Li M, Palmer B, Remling L, Li S, Yam P, et al. Safety and efficacy of a lentiviral vector containing three anti-HIV genes-CCR5 ribozyme, tat-rev siRNA, and TAR decoy-in SCID-hu mouse-derived T cells. Mol Ther. 2007;15(6):1182-8.
32. ClinicalTrials. gov: Gene Transfers for HIV Using Autologous T cells [Internet]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT0115 3646?term=gene+transfers+for+hiv+using+autologous+ t+cells&rank=1.
33. Lu X, Yu Q, Binder G, Chen Z, Slepushkina T, Rossi J, et al. Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance. J Virol. 2004;78(13):7079-88.
34. Mautino M, Morgan R. Potent inhibition of human immunodeficiency virus type 1 replication by conditionally replicating human immunodeficiency virus-based lentiviral vectors expressing envelope antisense mRNA. Hum Gene Ther. 2000;11(14):2025-37.
35. Humeau L, Binder G, Lu X, Slepushkin V, Merling R, Echeagaray P, et al. Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol Ther. 2004;9(6):902-13.
36. Lu X, Humeau L, Slepushkin V, Binder G, Yu Q, Slepushkina T, et al. Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol. J Gene Med. 2004;6(9):963-73.
37. Levine B, Humeau L, Boyer J, MacGregor R, Rebello T, Lu X, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA. 2006;103(46):17372-7.
38. VIRxSYS. com: HIV RNA Therapy 2009 [Internet]. Available from: http://www.virxsys.com/pages/humantherapies/hiv-rna-therapy.php.
39. Morgan R, Walker R, Carter C, Natarajan V, Tavel J, Bechtel C, et al. Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. Hum Gene Ther. 2005;16(9):1065-74.
40. Enzo. com. Research and Focus [Internet]. Available from: www.enzo.com/therapeutics.
41. Liu D, Conant M, Cowan M, Laurence J, Eden C, Dunn E, et al. Engraftment and development of HGTV43-transduced CD34+ PBSC in HIV-1 seropositive individuals. International Conference on AIDS; 2002, Jul 7-12; Barcelona, Spain.
42. An D, Donahue R, Kamata M, Poon B, Metzger M, Mao S, et al. Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc Natl Acad Sci USA. 2007;104(32):13110-5.
43. Anderson J, Walker J, Nolta J, Bauer G. Specific transduction of HIV-susceptible cells for CCR5 knockdown and resistance to HIV infection: a novel method for targeted gene therapy and intracellular immunization. J Acquir Immune Defic Syndr. 2009;52(2):152-61.
44. Kim S, Peer D, Kumar P, Subramanya S, Wu H, Asthana D, et al. RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther. 2010;18(2):370-6.
45. ter Brake O, Legrand N, von Eije K, Centlivre M, Spits H, Weijer K, et al. Evaluation of safety and efficacy of RNAi against HIV-1 in the human immune system (Rag-2(-/-)gammac(-/-) mouse model. Gene Ther. 2009;16(1):148-53.
46. Kumar P, Ban H, Kim S, Wu H, Pearson T, Greiner D, et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell. 2008;134(4):577-86.
47. Davis M, Zuckerman J, Choi C, Seligson D, Tolcher A, Alabi C, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464(7291):1067-70.
48. Syed M, Pervaiz S. Advances in Aptamers. Oligonucleotides. 2010;20(5):215-24.
49. Kohn D, Bauer G, Rice C, Rothschild J, Carbonaro D, Valdez P, et al. A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood. 1999;94(1):368-71.
50. Bahner I, Kearns K, Hao Q, Smogorzewska E, Kohn D. Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture. J Virol. 1996;70(7):4352-60.
51. Zhou J, Li H, Li S, Zaia J, Rossi J. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther. 2008;16(8):1481-9.
52. Zhou J, Rossi J. Aptamer-targeted cell-specific RNA interference. Silence. 2010;1(1):4.
53. Zhou J, Swiderski P, Li H, Zhang J, Neff C, Akkina R, et al. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res. 2009;37(9):3094-109.